Akebia Therapeutics just took a 26% hit, with the stock sliding to about US$0.95, as investors reacted to a quarter that put its valuation strain back in the spotlight. The immediate trigger was Q2 revenue of US$49.1 million and another quarterly net loss. The key issue is what that means for a stock that trades on a very low price to sales ratio and a large gap to modelled future cash flow value.

The short term looks painful on the screen. The bigger question is how long Akebia can run its loss making kidney portfolio before the balance between cash, debt and future value starts to really matter.

Is Akebia Therapeutics a deep value setup at a US$0.95 share price, or is the low price to sales ratio simply mirroring its ongoing losses and insider selling risk? Compare that gap between market price and modelled fair value in our valuation analysis for Akebia Therapeutics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: US$49.1 million vs. US$62.5 million (decline of about 21%)
• Net Income/Loss, Q2 2026 vs Q2 2025: loss of US$8.9 million vs. profit of US$0.2 million (moved back into loss making territory)
• Basic EPS, Q2 2026 vs Q2 2025: loss of US$0.03 per share vs. profit of US$0.00 per share (swing back to a per share loss)
• Vafseo Net Product Revenue, Q2 2026 vs Q2 2025: US$21.3 million vs. about US$13.3 million (growth of about 60%)

Prefer clean charts instead of scrolling through another page of earnings tables and cash flow figures? See Akebia Therapeutics' full financial picture with a visual focus on valuation in the interactive company report for Akebia Therapeutics.

Akebia bull story leans heavily on Vafseo execution

Bulls argue Akebia Therapeutics can offset pressure on legacy Auryxia through rapid Vafseo uptake, better per patient economics, and a focused kidney portfolio. Recent results give that view some real milestones. Vafseo net product revenue reached US$21.3 million with about 34% sequential growth and around 60% growth year on year. Active patients moved past 10,000 and the prescriber base grew about 17% quarter on quarter, with roughly one third of prescribers now outside U.S. Renal Care. That points to traction beyond a single partner. A first refill rate near 89% supports the idea of improving adherence and revenue per patient.

The early stopping of the VOICE outcomes trial for superiority on mortality plus hospitalization directly supports the claim that Vafseo can become a standard therapy in dialysis anemia. Together, these data points show the growth engine bulls focus on is at least turning over.

Compare that operational progress with how institutions are resetting their expectations after a 26% share price drop. See the consensus price target analysis for Akebia Therapeutics to check where analysts think Akebia Therapeutics should trade next.

Akebia bear case focuses on fragility beneath Vafseo

The core bearish worry for Akebia Therapeutics is that this is a single product story with fragile economics once Vafseo momentum is stripped out. This quarter gives that concern some backing. Total revenue fell to US$49.1 million while the company swung from a small profit to a net loss of US$8.9 million. That shift came as Auryxia sales dropped from US$47.2 million to US$25.5 million, which is consistent with the kind of erosion bears expect from generic pressure.

Bears also point to funding and dilution risk. Management now references existing cash of roughly US$155.5 million and a planned refinancing intended to fund at least two years of operations. That highlights an ongoing need to access capital rather than removing the concern. The 26% one day share price fall shows the market still treats protocol changes and channel moves as material execution risks.

Scan our independent risk analysis for Akebia Therapeutics which shows 3 important warning signs to see whether Akebia Therapeutics' share price volatility and funding needs hint at deeper structural vulnerabilities.

Stay Ahead Of Your Next Move

If Akebia Therapeutics catching a 26% drop after its latest quarter has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the story around Vafseo and Auryxia evolves. Once you take a position, keep your focus with the Portfolio Command Center that cuts through noise and highlights only the key developments that could affect your holdings. For the longer term, tap into crowd insight through the Community so you can see how other investors are thinking about the same risks and potential catalysts. By spotting shifts in sentiment, fundamentals and risk early, you give yourself a better chance of staying ahead of the market rather than reacting to it.

Seeking Alternatives Beyond Akebia Therapeutics

Fresh stock ideas can move from quiet accumulation to full breakout before most investors even notice. Scan these curated lists while the data is still under the radar for now and consider them carefully.

• Spot potential breakout cash generators early by scanning our curated 50 high quality undervalued stocks that still look mispriced before momentum chasers catch on.
• Get ahead of the AI infrastructure story by running through 56 AI infrastructure stocks where real businesses power the chips, data centers and networks behind the headlines.
• Position around the energy transition with 36 power grid technology and infrastructure stocks that could benefit if grid upgrades, transmission builds and reliability spending continue to develop.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.